Equities research analysts predict that Microbot Medical Inc (NASDAQ:MBOT) will post earnings of ($0.36) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Microbot Medical’s earnings. Microbot Medical posted earnings of ($0.59) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 39%. The firm is scheduled to announce its next earnings report on Wednesday, November 13th.
According to Zacks, analysts expect that Microbot Medical will report full year earnings of ($1.33) per share for the current year, with EPS estimates ranging from ($1.55) to ($1.11). For the next financial year, analysts forecast that the company will report earnings of ($0.84) per share, with EPS estimates ranging from ($1.23) to ($0.44). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Microbot Medical.
Microbot Medical (NASDAQ:MBOT) last announced its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.09.
MBOT has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Microbot Medical in a research note on Wednesday, September 11th. ValuEngine cut shares of Microbot Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, September 10th.
Several hedge funds have recently added to or reduced their stakes in MBOT. Morgan Stanley increased its stake in Microbot Medical by 77.0% during the second quarter. Morgan Stanley now owns 6,316 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 2,748 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in Microbot Medical in the second quarter worth approximately $45,000. BlackRock Inc. increased its holdings in Microbot Medical by 5.7% in the second quarter. BlackRock Inc. now owns 183,520 shares of the biotechnology company’s stock worth $945,000 after buying an additional 9,906 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Microbot Medical by 5.5% in the second quarter. Renaissance Technologies LLC now owns 206,887 shares of the biotechnology company’s stock worth $1,065,000 after buying an additional 10,838 shares during the last quarter. Institutional investors own 14.79% of the company’s stock.
Shares of Microbot Medical stock traded up $0.02 during mid-day trading on Tuesday, hitting $6.55. The stock had a trading volume of 29,125 shares, compared to its average volume of 220,767. The firm has a 50-day moving average of $5.92 and a two-hundred day moving average of $6.47. Microbot Medical has a 12-month low of $1.38 and a 12-month high of $19.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.69 and a current ratio of 2.69.
About Microbot Medical
Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.